Acute myeloid leukemia (AML) is the most common form of adult leukemia. The transcription factor fusion CBFβ-SMMHC (core binding factor β and the smooth-muscle myosin heavy chain), expressed in AML with the chromosome inversion inv(16)(p13q22), outcompetes wild-type CBFβ for binding to the transcription factor RUNX1, deregulates RUNX1 activity in hematopoiesis, and induces AML. Current inv(16) AML treatment with nonselective cytotoxic chemotherapy results in a good initial response but limited long-term survival. Here, we report the development of a protein-protein interaction inhibitor, AI-10-49, that selectively binds to CBFβ-SMMHC and disrupts its binding to RUNX1. AI-10-49 restores RUNX1 transcriptional activity, displays favorable pharmacokinetics, and delays leukemia progression in mice. Treatment of primary inv(16) AML patient blasts with AI-10-49 triggers selective cell death. These data suggest that direct inhibition of the oncogenic CBFβ-SMMHC fusion protein may be an effective therapeutic approach for inv(16) AML, and they provide support for transcription factor targeted therapy in other cancers.
A cute myeloid leukemia (AML) is the most common form of adult leukemia (1) . Longterm survival for AML remains poor and varies with the mutational composition of the leukemic cells. The transcription factor fusion CBFb-SMMHC (fusion of core binding factor b and smooth-muscle myosin heavy chain), expressed in AML with the chromosome inversion inv(16)(p13q22), cooperates with activating mutations in components of cytokine signaling pathways in leukemia transformation (2) (3) (4) (5) . CBFb is a component of the heterodimeric transcription factor core binding factor, where it binds to RUNX proteins and enhances their affinity for DNA (6) , and the resulting complex plays a key role in regulating hematopoiesis (7) . CBFb-SMMHC outcompetes CBFb for binding to RUNX1 (8) , deregulates RUNX1 transcription factor activity in hematopoiesis, and induces AML. Current inv(16) AML treatment with nonselective cytotoxic chemotherapy results in a good initial response but limited long-term survival. Studies in mice and patient samples support the concept that inv(16) is a driver mutation that generates preleukemic progenitor cells that, upon acquisition of additional cooperating mutations, progress to leukemia (3, 4, (9) (10) (11) (12) .
To develop a targeted inhibitor of CBFb-SMMHC function, we used a previously described fluorescence resonance energy transfer (FRET) assay (13) with Venus-CBFb-SMMHC replacing VenusCBFb ( fig. S1 ) to screen the National Cancer Institute, NIH, Diversity Set for compounds that inhibit the binding of CBFb-SMMHC to the RUNX1 Runt domain. This screen identified the active compound AI-4-57 with a 50% inhibitory concentration (IC 50 ) of 22 mM, whereas AI-4-88, a derivative lacking the methoxy functionality, is inactive (Table 1) . Changes in the chemical shifts in a nuclear magnetic resonance (NMR) spectrum of a protein upon binding of a small molecule are a powerful method to confirm binding to a protein. We recorded two-dimensional 2D 15 N-1 H heteronuclear single quantum coherence (HSQC) spectra and 1D saturation transfer difference (STD) NMR experiments of AI-4-57 with CBFb and the Runt domain. No interaction was observed for the Runt domain, but we can demonstrate chemical shift perturbations in the HSQC spectrum of CBFb upon addition of AI-4-57 (Fig. 1A) and no changes upon addition of the inactive derivative AI-4-88 ( fig. S2 ), which establishes that the compound binds to CBFb. Chemical shift perturbations in the backbone and in two aromatic side chains [tryptophan at position 113 (W113) and tyrosine at position 96 (Y96)] indicate that the compound binds in a site spatially close to CBFb but not on the protein-protein interaction surface on CBFb, that is, it acts in an allosteric manner to inhibit binding ( fig. S3) .
We have shown that a reduced dosage of CBFb in the presence of a CBFb-SMMHC knockin allele enhances leukemogenesis in mice (14) and argue that selectivity for CBFb-SMMHC versus CBFb is critical for in vivo utility. To achieve such specificity, we have taken advantage of the state of the two in solution: CBFb-SMMHC is oligomeric, whereas CBFb is monomeric (8, 15) and have applied the principles of polyvalency (16, 17) to develop derivatives of AI-4-57 with enhanced potency and selectivity (Fig. 1B) . Substitutions at the five position of the pyridine ring do not affect activity (Table 1) , so we have utilized polyethylene glycol-based linkers at this position to create bivalent derivatives with 5-, 7-, 10-, and 16-atom linker lengths (Table 1) . Measurement of the IC 50 values with the FRET assay (Fig. 1C) shows that the five-atom linker compound has less activity, but the longer linker compounds show potent inhibition with the seven-atom linker inhibitor (AI-4-83) yielding a 350 nM IC 50 , which corresponds to a 63-fold enhancement over the monovalent compound (Fig. 1D and Table 1 ). In addition, AI-4-83 achieves >10-fold dissociation of CBFb-SMMHC and RUNX1 Runt domain at saturating concentrations (Fig. 1D) .
The activity of the bivalent inhibitors on cell growth was tested in three human leukemia cell lines [ME-1, inv(16) cell line; Kasumi-1, t(8;21) cell line; and U937, lymphoma cell line] by using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) conversion assay. Mimicking the results obtained with the FRET assay, even in terms of relative efficacy, growth of inv(16) cell line ME-1 was sensitive to compounds AI-4-71, AI-4-83, and AI-4-82 but not to AI-10-19 (Fig. 1E) . In contrast, growth of non-inv(16) cell lines U937 and Kasumi-1 was unaffected over the same concentration range ( fig. S4, A and B) , which demonstrated a high degree of specificity and suggested that the activity of these bivalent compounds was on target.
Analysis of the pharmacokinetic properties of AI-4-57 showed that the compound has a short half-life (t 1/2 = 37 min) in mouse plasma ( fig. S5 ) and that loss of the methyl group from the methoxy functionality is the primary metabolite. Trifluoromethoxy (CF 3 O) substitutions have been shown to be less reactive (18, 19) , so we synthesized AI-10-47 with this substitution. FRET measurements show that this substitution actually enhances the activity of the monovalent compound ( Table 1) . Measurements of stability in liver microsomes showed that AI-10-47 reduced the metabolic liability and so justified the synthesis of the bivalent derivative AI-10-49 (Table  1) . AI-10-49 is potent (FRET IC 50 = 260 nM) ( Table 1) [isothermal titration calorimetry (ITC) measurements yielded a dissociation constant (K D ) = 168 nM] ( fig. S6 ), has improved in vivo pharmacokinetic properties (t 1/2 = 380 min) ( fig. S5) , and has enhanced inhibitory activity on ME-1 cell growth (IC 50 = 0.6 mM) (Fig. 1F ) compared with the parent protonated bivalent compound AI-4-83 (IC 50 of~3 mM) (Fig. 1E) . Note that AI-10-49 showed negligible activity (IC 50 > 25 mM) in normal human bone marrow cells (Fig. 1G ), which indicated a robust potential therapeutic window. In a panel of 11 human leukemia cell lines, ME-1 cells were the only cell line highly sensitive to AI-10-49 ( fig. S7 ).
The specificity of AI-10-49 in disrupting endogenous RUNX1 binding to CBFb-SMMHC versus CBFb was assessed in ME-1 cells. AI-10-49 effectively dissociated RUNX1 from CBFb-SMMHC, with 90% dissociation after 6 hours of treatment, whereas it had only a modest effect on CBFb-RUNX1 association ( Fig. 2A) . The stability of RUNX1, CBFb, and CBFb-SMMHC was not affected by AI-10-49 ( fig. S8A) . Expression of the RUNX1-regulated genes RUNX3, CSF1R, and CEBPA is repressed by CBFb-SMMHC in inv(16) AML (20) (21) (22) . Previous studies have shown decreased RUNX1 binding to target genes in the presence of CBFb-SMMHC (23, 24) , which suggests that CBFb-SMMHC represses RUNX1 target genes by blocking binding of RUNX1 to target DNA sites (Fig. 2B) . Consistent with this model, chromatin-immunoprecipitation (ChIP) assays showed that treatment of ME-1 cells for 6 hours with AI-10-49 increased RUNX1 occupancy 8-, 2.2-, and 8-fold at the RUNX3, CSF1R, and CEBPA promoters, respectively, whereas no enrichment was observed at control loci ( Fig. 2C and fig. S8 , B and C). In accordance with this, treatment of ME-1 cells for 6 or 12 hours with AI-10-49 increased expression of RUNX3, CSF1R, and CEBPA but had no effect on control gene PIN1 (Fig.   2D ). Neither of these effects was observed in inv(16)-negative U937 cells. These data establish AI-10-49 selectivity in inhibiting CBFb-SMMHC binding to RUNX1 and validate our approach of using bivalent inhibitors to achieve this specificity.
Up to 90% of inv(16) AML patients have cooperating mutations in components of the receptor tyrosine kinase pathway, including N-RAS and c-Kit (25) . We have recently developed an efficient mouse model of inv (16) :Ras +/G12D leukemic cells, waited 5 days for engraftment, and then treated mice with vehicle [dimethyl sulfoxide (DMSO)] or 200 mg/kg of body weight AI-10-49 for 10 days, and assessed the effect on disease latency. As shown in Fig. 3A , vehicle-treated mice succumbed to leukemia with a median latency of 33.5 days, whereas AI-10-49-treated mice survived significantly longer (median latency = 61 days; P = 2.7 × 10
−6
). Thus, transient treatment with AI-10-49 reduces leukemia expansion in vivo. Although we have not assessed toxicity after longterm exposure, after 7 days of administration of AI-10-49, we observe no evidence of toxicity (figs. S9 to S11).
To test the potential utility of AI-10-49 for use in human inv(16) leukemia treatment, we evaluated the survival of four primary inv(16) AML cell samples treated for 48 hours with a dose range of monovalent AI-10-47 and bivalent AI-10-49. As shown in Fig. 3B , the viability of inv(16) patient cells was reduced by treatment with AI-10-49 at 5 and 10 mM concentrations (individual dose-response experiments are shown in fig. S12 ). Note that the bivalent AI-10-49 was more potent than the monovalent compound AI-10-47 and so recapitulated the effects observed in the human inv(16) cell line ME-1. In contrast, the viability of normal karyotype AML samples was not affected by AI-10-49 treatment (Fig. 3C) . Analysis of an additional set of five AML samples revealed that AI-10-49 treatment specifically reduces the viability of inv(16) leukemic cells without having an apparent effect on their differentiation ( fig. S13 ). AI-10-49 specificity was also evident when we assessed the ability of AML cells to form colonies by evaluating colony-forming units (CFUs) after compound exposure. The ability of inv(16) AML cells to form CFUs was selectively reduced by AI-10-49 when compared with normal karyotype and t(8;21) AML patient samples (Fig. 3D ). This inhibitory effect was dose-dependent (40 and 60% at 5 and 10 mM, respectively) ( (8)]. Three independent measurements were performed, and their average and standard deviation were used for IC 50 data fitting. (E) Dose-dependent effect of a 24-hour treatment of ME-1 cells with bivalent inhibitors with varying linker lengths measured by MTT assay and normalized to the DMSO-treated group. Each symbol represents the mean of triplicate experiments; error bars represent the SD. (F and G) Dose-dependent effect of AI-10-47 (red) and AI-10-49 (black) treatment for 48 hours; (F) ME-1 cells were assessed by annexin V and 7-amino-actinomycin (7AAD) viability staining, and (G) human bone marrow cells were assessed by MTT assay. The data were normalized to the DMSOtreated group. Each data point represents the mean of triplicate experiments; error bars represent the SD.
whereas there was no change in CFUs of AML cells treated with AI-10-47, AML cells with normal karyotype (Fig. 3F) , or CD34+ cord blood cells (Fig. 3G) . These studies show that AI-10-49 selectively inhibits viability and CFU capacity in inv(16) AML blasts, whereas it has negligible effects on AML blasts with normal karyotype or, importantly, on normal human hematopoietic progenitors.
Dysregulated gene expression is a hallmark of cancer and is particularly important for the maintenance of cancer stem-cell properties, such as self-renewal, which lead to relapse. As such, the targeting of proteins that drive transcriptional dysregulation, so-called "transcription therapy," represents an avenue for drug development with immense potential. A number of fusion proteins involving transcription factors have been identified as drivers of disease in leukemia (27) ; sarcoma (28) ; and, recently, in prostate cancer (29) , which provide excellent targets for therapeutic intervention. Our results provide a proof-ofprinciple for this approach, as AI-10-49 specifically inhibits CBFb-SMMHC-RUNX binding and shows efficacy against CBFb-SMMHC-driven leukemia in mice with no obvious side effects. Specificity of action is a key component in the development of a targeted drug. Imatinib, for example, shows excellent specificity, and its efficacy in chronic myelogenous leukemia is clearly a result of effective inhibition of the BCR-ABL fusion protein that drives chronic myelogenous leukemia. However, even this highly selective agent inhibits both the BCR-ABL fusion protein, as well as wild-type ABL.
The "Holy Grail," as it were, of targeted therapy with fusion or mutated protein drivers of cancer is to achieve inhibition of the fusion or mutated protein with little to no effect on the wild-type protein. This study demonstrates that AI-10-49 represents an example of such selectivity for inv (16) , and CEBPA in ME-1 and U937 cells treated with 1 mM AI-10-49 for 6 and 12 hours, and normalized to the DMSO control group. Each symbol represents the mean of triplicate experiments; error bars represent the SD. For all panels, significance was calculated as unpaired t-test, *P < 0.05, or ***P < 0.001. action, identity of active species, and proven utility. Development of agents, like AI-10-49, which can inhibit the driver mutation(s) in specific types of cancer, is essential for better therapeutic outcomes for patients.
In summary, AI-10-49 is a potent and specific first-generation CBFb-SMMHC lead compound that induces cell death in inv(16) leukemic cells. The work described here provides additional evidence that transcription factor drivers of cancer can be directly targeted. Using a limiting dilution approach, we found that many individual naïve B cells produced only one type of effector cell subset, whereas others produced all subsets. The capacity to differentiate into multiple subsets was a characteristic of clonal populations that divided many times and resisted apoptosis, but was independent of isotype switching. Antigen receptor affinity also influenced effector cell differentiation. These findings suggest that diverse effector cell types arise in the primary immune response as a result of heterogeneity in responses by individual naïve B cells.
A ntibody production results from a differentiation process that begins when the surface form of immunoglobulin (Ig) known as the B cell receptor (BCR) on a naïve B cell binds an antigen (1, 2) . BCR signaling causes the B cell to migrate to the border of the T cell zone, where it receives signals from T cells (3, 4) . These signals cause the B cell to proliferate and differentiate into several types of effector cells, including short-lived plasma cells, germinal center (GC) cells, and GC-independent memory cells (1, 2) . GC cells then undergo somatic hypermutation in their Ig genes, and cells with mutations that improve BCR affinity for antigen are selected to become GC-dependent memory or plasma cells (1, 2) .
Despite the importance of this process to immunity and vaccination, it is unclear how individual naïve B cells simultaneously produce all of the early effector cell types. Some studies suggest that different naïve B cell clones only produce a single effector subset, depending on BCR affinity for antigen (5) (6) (7) (8) or intrinsic stochastic biases of the responding clonal population (9) . Alternatively, each naïve B cell may produce all effector cell types, as suggested by recent work on naïve T cells (10) (11) (12) (13) .
We addressed these possibilities by tracking the fates of antigen-specific naïve B cells during the primary immune response to the protein antigen allophycocyanin (APC). Using a sensitive antigen-based cell enrichment method (14), we found that the spleen and lymph nodes of a C57BL/6 (B6) mouse contained about 4000 polyclonal APC-specific naïve B cells, which produced 100,000 effector cells 7 days after immunization with APC in complete Freund's adjuvant (CFA) (Fig. 1, A and B (Fig. 1, C and D, and fig. S1 ).
In vivo limiting dilution was used to assess the multipotentiality of a single APC-specific naïve B cell. Before limiting dilution could be achieved, it was necessary to determine the fraction of APCspecific naïve B cells that responded to immunization. Twenty million B cells from CD45.1 + mice that were never exposed to APC were labeled with the cell division-tracking dye carboxyfluorescein succinimidyl ester (CFSE) (16) and transferred into CD45.2 + recipients. Donor-derived APC-specific B cells were CFSE high 7 days after immunization with CFA alone, which is indicative of cells that had not divided (Fig. 1E) . After the injection of APC in CFA, most donor APCspecific B cells were CFSE low , and the CFSE high population was 33% smaller than in mice injected with CFA alone (Fig. 1, E and F) . These results indicated that one in three APC-specific naïve B cells, or 1 in 60,000 total B cells, proliferated in mice immunized with APC. The 33% response frequency of APC-specific naïve B cells was not a limitation of the CFSE dilution assay, because 97 to 100% of naïve MD4 B cells proliferated ( fig. S2 ) after the injection of hen egg lysozyme (HEL) or duck egg lysozyme (DEL), for which the MD4 BCR has a high or medium affinity, respectively (17) . Thus, the 33% responder frequency was a feature of the polyclonal APC-specific B cell population under these immunization conditions.
Limiting dilution experiments were then performed, based on the above knowledge and the fact that 7.7 T 2.8% (n = 116 recipients) of donor naïve B cells survive after transfer. (Fig. 2A) . All mice that received 2 × 10 6 B cells contained a defined population of CD45.1 + donor-derived APC-specific B cells that had proliferated in response to APC (Fig. 2, A and  B) . In contrast, 19% (74 out of 384) of mice that received the limiting number of 0.2 × 10 6 B cells contained donor-derived APC-responsive B cells (Fig. 2, B and C) . Based on the Poisson distribution (18) , over 91% of the donor-derived populations in this group were the progeny of a single naïve B cell.
Extensive effector cell heterogeneity was observed in the progeny of individual naïve B cells. Single naïve B cells produced between 4 and 957 progeny, with a median of 16 (Fig. 2C) . The polyclonal naïve cell populations of recipient origin
